Paralysis, Paraplegia, Quadraplegia, Tetraplegia
Conditions
Brief summary
A study comparing short-term delivery of epidural spinal stimulation versus transcutaneous spinal stimulation.
Detailed description
The purpose of this study is to compare spinal motor nerve response to electrical stimulation delivered directly to the epidural space, and delivered through the skin (transcutaneously), and to measure any changes in motor performance over the course of about 5 months, during and after using one of the two types of stimulation.
Interventions
Abbott percutaneous trial lead for epidural neurostimulation (Model 3086) Ripple Neuromed Nomad Neurostimulation System
Digitimer DS8R Bipolar Constant Current Stimulator
Sponsors
Study design
Eligibility
Inclusion criteria
* Spinal cord injury due to trauma located at or above the tenth thoracic vertebrae (T10) * American Spinal Injury Association grading scale of A-D (2 from each) below the level of SCI * Intact spinal reflexes below the level of SCI * At least 1-year post-SCI * At least 22 years of age * Willing to use medically acceptable methods of contraception, if female and of child-bearing potential
Exclusion criteria
* Currently a prison inmate, or awaiting trial, related to criminal activity * Pregnancy at the time of enrollment * History of chronic and/or treatment resistant urinary tract infection * Unhealed decubitus ulcer * Unhealed skeletal fracture * Untreated clinical diagnosis of depression * Undergoing, or planning to undergo, diathermy treatment * Active participation in another interventional clinical trial * Presence of conditions or disorders which require MRI monitoring * A history of coagulopathy or other significant cardiac or medical risk factors for surgery * Current use of a ventilator * Clinically diagnosed cardiopulmonary complications such as chronic obstructive pulmonary disease, cardiac failure, or heart arrhythmia that contraindicate changes in body position such as supine-to-sit-to-stand activities, prolonged standing, or stepping * History of frequent hypotension characterized by light headedness, or loss of consciousness * History of frequent hypertension characterized by headache, or bradycardia * History of frequent, severe, autonomic dysreflexia * Any illness or condition which, based on the research team's assessment, will compromise with the patient's ability to comply with the protocol, patient safety, or the validity of the data collected during this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Electromyography | Through study completion; an average of 5 months. | Change in voltage measurements in major muscle groups below the level of injury. Specifically, change in soleus root mean square voltage during standing with and without stimulation. |
| Foot Pressure | Beginning of intervention to end of intervention, an average of 17 days. | Change in measurements of foot pressure in kilograms through shoe-insole pressure sensors. |
| Somatosensory Evoked Potentials | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurements of change in voltage in the conduction of electricity through the peripheral nerves, cervical and lumbosacral spinal cord, deep brain structures, and sensory cortex, using surface electrodes. |
| Transcranial Magnetic Stimulation Motor Evoked Potentials | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurement of the threshold percentage change in voltage between pre-intervention and post-intervention in the first trapezius or deltoid muscle activated. |
| Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Change sensory and motor function impairment using the American Spinal Injury Association Impairment Scale. Individuals are classified from A (complete SCI) to E (normal function). 28 dermatomes and 10 key muscles are assessed bilaterally. Summed results produce overall sensory and motor scores and combine with evaluation of anal sensory and motor function in determination of AIS classification. Sensory scores are rated 0 (sensation absent) to 2 (normal), bilaterally for each of 28 dermatomes. Muscle function is rated 0 (total paralysis) to 5 (active movement, full range of motion against significant resistance) for each myotome. Upper Extremity Motor Subscores and Lower Extremity Motor Subscores are scored from 0 to 50; the ASIA Motor Score is scored from 0 to 100. The presence of deep anal pressure and voluntary anal contraction are assessed as a yes/no; absence of these, in addition to sensory scores of 0 at S4-5 indicate a Complete injury (otherwise, the injury is Incomplete). |
| Patient-reported Bowel Function | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurement of change in bowel function using the Neurogenic Bowel Dysfunction Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bowel symptoms. The total score ranges between 0 and 44 points. A higher total score indicates more severe bowel symptoms. |
| Patient-reported Bladder Function | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurement of change in bladder function using the Neurogenic Bladder Symptom Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bladder symptoms. The total score can range from 0 (no symptoms at all) to 74 (maximum symptoms). |
| Male Patient-reported Sexual Function (1) | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurement of change in erectile dysfunction using the Sexual Health Inventory for Men (SHIM). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total score can range from 1 to 25, with a lower number indicating more severe erectile dysfunction. |
| Male Patient-reported Sexual Function (2) | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurement of change in erectile dysfunction using the International Index for Erectile Function (IIEF). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total scores range from 5 to 25, with a lower score indicating more severe erectile dysfunction. |
| Female Patient-reported Sexual Function | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Measurement of change in sexual function using the Female Sexual Function Index (FSFI). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better sexual function, and totaled for a score which categorizes severity of sexual dysfunction. |
| Spasticity | Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported. | Change in measurements of spasticity using the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET). Answers to qualitative questions are rated from -3 to +3, with a higher positive number indicating more helpful symptoms, and a lower negative number indicating more problematic symptoms. Questions may also be answered as not applicable (N/A), which do not generate a score. Scores are totaled for a score which categorizes the overall positive or negative impact of a subject's spasticity symptoms. Total score can range from -105 (negative impact) to +105 (positive impact), and the score is averaged by total positive or negative score divided by the number of applicable answers. |
| Neurostimulation User Experience | End of intervention, an average of 4 weeks | Rating of the subject's perception of individual aspects of spinal stimulation using the User Experience Questionnaire (UEQ), a survey including 26 descriptive terms and their antonyms. A scoring scale ranging from 1 to 7 determines how closely the subject feels the term or its antonym applies to the intervention, with lower numbers indicating agreement with the term, and higher numbers indicating agreement with the antonym. The terms and antonyms describe a positive and negative perception of each item. Subscales grouping terms into like categories average scores into a 7 point range from -3 to +3, with negative averages associated with negative perceptions, and positive averages associated with positive perceptions. |
| Overground Ambulation [as Appropriate to the Subject] | Baseline, 4 Weeks, 8 Weeks, and 20 Weeks | Measurement of changes in overground mobility as measured by the Modified 6 Minute Walk Test. Trainers will assess the distance in meters which the subject can cover in 6 minutes, with a greater distance characterizing better overground mobility. |
| Trunk Stability | Beginning of intervention to end of intervention, an average of 17 days, 8 weeks post beginning of intervention, 20 weeks post beginning of intervention; change from beginning of intervention at week 20 reported. | Changes in trunk stability based on stable forward reach measured in centimeters, with a greater distance of forward reach characterizing greater trunk stability. Specifically, change in forward reach at the end of the study when comparing stimulation assisted reach and non-stimulation assisted reach. |
| Neurostimulator Lead Location and Migration [Epidural Group Only] | Pre-intervention and 4 weeks post-intervention | Evaluation of current array location via CT. |
| Bladder Function Testing | Beginning of study, prior to initiating intervention; End of 4 weeks of intervention. | Change in measurements of bladder function (end fill detrusor value) utilizing a urodynamic test consisting of a filling phase and a voiding phase cystometrogram along with perineal patch muscle electromyography. |
Countries
United States
Participant flow
Recruitment details
Recruitment was conducted from March 4, 2022 to October 11, 2022 within a medical clinic.
Participants by arm
| Arm | Count |
|---|---|
| Percutaneous Epidural Stimulation Epidural spinal stimulation will be delivered via percutaneously implanted electrodes during rehabilitation. All implanted electrodes will be removed at the end of trial participation. The effects of epidural stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
Percutaneous epidural electrical spinal stimulation: Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)
Ripple Neuromed Nomad Neurostimulation System | 3 |
| Transcutaneous Epidural Stimulation Transcutaneous spinal stimulation will be delivered via skin surface-level electrodes during rehabilitation. The effects of transcutaneous stimulation will be recorded via electrophysiological and biomechanical metrics described within the outcomes measures.
Transcutaneous electrical spinal stimulation: Digitimer DS8R Bipolar Constant Current Stimulator | 3 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lengthy COVID-19 infection interrupted intervention to an unsatisfactory degree. | 0 | 1 |
Baseline characteristics
| Characteristic | Percutaneous Epidural Stimulation | Transcutaneous Epidural Stimulation | Total |
|---|---|---|---|
| Age, Customized 22-29 | 2 Participants | 2 Participants | 4 Participants |
| Age, Customized 30-39 | 0 Participants | 1 Participants | 1 Participants |
| Age, Customized 40-49 | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Multiracial | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 3 Participants | 3 Participants | 6 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 2 Participants | 3 Participants | 5 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 3 Participants | 3 Participants | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 |
| other Total, other adverse events | 1 / 3 | 3 / 3 |
| serious Total, serious adverse events | 0 / 3 | 1 / 3 |
Outcome results
Bladder Function Testing
Change in measurements of bladder function (end fill detrusor value) utilizing a urodynamic test consisting of a filling phase and a voiding phase cystometrogram along with perineal patch muscle electromyography.
Time frame: Beginning of study, prior to initiating intervention; End of 4 weeks of intervention.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Percutaneous Epidural Stimulation | Bladder Function Testing | Pre-intervention | 21 cm H2O | Standard Deviation 15.769168 |
| Percutaneous Epidural Stimulation | Bladder Function Testing | Post-intervention | 54.666667 cm H2O | Standard Deviation 32.148959 |
| Transcutaneous Epidural Stimulation | Bladder Function Testing | Pre-intervention | 10.5 cm H2O | Standard Deviation 5.5 |
| Transcutaneous Epidural Stimulation | Bladder Function Testing | Post-intervention | 15 cm H2O | Standard Deviation 15 |
Electromyography
Change in voltage measurements in major muscle groups below the level of injury. Specifically, change in soleus root mean square voltage during standing with and without stimulation.
Time frame: Through study completion; an average of 5 months.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Percutaneous Epidural Stimulation | Electromyography | 0.00017507 volts | Standard Deviation 0.04279603 |
| Transcutaneous Epidural Stimulation | Electromyography | 0.00006740 volts | Standard Deviation 0.0591704 |
Female Patient-reported Sexual Function
Measurement of change in sexual function using the Female Sexual Function Index (FSFI). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better sexual function, and totaled for a score which categorizes severity of sexual dysfunction.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
Population: No female participants were enrolled.
Foot Pressure
Change in measurements of foot pressure in kilograms through shoe-insole pressure sensors.
Time frame: Beginning of intervention to end of intervention, an average of 17 days.
Population: Increase in the difference in total loading force when standing, between beginning and end of intervention (an average of 17 days), with and without stimulation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Percutaneous Epidural Stimulation | Foot Pressure | End of intervention | 40 percentage of loading force increase | Standard Deviation 34 |
| Percutaneous Epidural Stimulation | Foot Pressure | Beginning of intervention | 6 percentage of loading force increase | Standard Deviation 9 |
| Transcutaneous Epidural Stimulation | Foot Pressure | Beginning of intervention | 0 percentage of loading force increase | Standard Deviation 0 |
| Transcutaneous Epidural Stimulation | Foot Pressure | End of intervention | 0 percentage of loading force increase | Standard Deviation 0 |
Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury
Change sensory and motor function impairment using the American Spinal Injury Association Impairment Scale. Individuals are classified from A (complete SCI) to E (normal function). 28 dermatomes and 10 key muscles are assessed bilaterally. Summed results produce overall sensory and motor scores and combine with evaluation of anal sensory and motor function in determination of AIS classification. Sensory scores are rated 0 (sensation absent) to 2 (normal), bilaterally for each of 28 dermatomes. Muscle function is rated 0 (total paralysis) to 5 (active movement, full range of motion against significant resistance) for each myotome. Upper Extremity Motor Subscores and Lower Extremity Motor Subscores are scored from 0 to 50; the ASIA Motor Score is scored from 0 to 100. The presence of deep anal pressure and voluntary anal contraction are assessed as a yes/no; absence of these, in addition to sensory scores of 0 at S4-5 indicate a Complete injury (otherwise, the injury is Incomplete).
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Percutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change between Complete (C) and Incomplete (I) designations | 0 Participants |
| Percutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change in ASIA Impairment Scale (AIS) rating | 0 Participants |
| Percutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change in sensation of Deep Anal Pressure (DAP) | 0 Participants |
| Percutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change in Voluntary Anal Contraction (VAC) | 0 Participants |
| Transcutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change in Voluntary Anal Contraction (VAC) | 0 Participants |
| Transcutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change between Complete (C) and Incomplete (I) designations | 0 Participants |
| Transcutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change in sensation of Deep Anal Pressure (DAP) | 0 Participants |
| Transcutaneous Epidural Stimulation | Injury Severity: International Standards for Neurological Classification of Spinal Cord Injury | Change in ASIA Impairment Scale (AIS) rating | 0 Participants |
Male Patient-reported Sexual Function (1)
Measurement of change in erectile dysfunction using the Sexual Health Inventory for Men (SHIM). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total score can range from 1 to 25, with a lower number indicating more severe erectile dysfunction.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Percutaneous Epidural Stimulation | Male Patient-reported Sexual Function (1) | -6.3 Score on a scale |
| Transcutaneous Epidural Stimulation | Male Patient-reported Sexual Function (1) | 0 Score on a scale |
Male Patient-reported Sexual Function (2)
Measurement of change in erectile dysfunction using the International Index for Erectile Function (IIEF). Answers to qualitative questions are rated from 0 to 5, with a higher number indicating better erectile function, and totaled for a score which categorizes severity of erectile dysfunction. Total scores range from 5 to 25, with a lower score indicating more severe erectile dysfunction.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Percutaneous Epidural Stimulation | Male Patient-reported Sexual Function (2) | -23.3 Score on a scale |
| Transcutaneous Epidural Stimulation | Male Patient-reported Sexual Function (2) | -1.5 Score on a scale |
Neurostimulation User Experience
Rating of the subject's perception of individual aspects of spinal stimulation using the User Experience Questionnaire (UEQ), a survey including 26 descriptive terms and their antonyms. A scoring scale ranging from 1 to 7 determines how closely the subject feels the term or its antonym applies to the intervention, with lower numbers indicating agreement with the term, and higher numbers indicating agreement with the antonym. The terms and antonyms describe a positive and negative perception of each item. Subscales grouping terms into like categories average scores into a 7 point range from -3 to +3, with negative averages associated with negative perceptions, and positive averages associated with positive perceptions.
Time frame: End of intervention, an average of 4 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Percutaneous Epidural Stimulation | Neurostimulation User Experience | Attractiveness | 3 Score on a scale | Standard Deviation 0 |
| Percutaneous Epidural Stimulation | Neurostimulation User Experience | Perspicuity | 1.5 Score on a scale | Standard Deviation 0.707 |
| Percutaneous Epidural Stimulation | Neurostimulation User Experience | Efficiency | 2.583 Score on a scale | Standard Deviation 0.382 |
| Percutaneous Epidural Stimulation | Neurostimulation User Experience | Dependability | 2.083 Score on a scale | Standard Deviation 0.52 |
| Percutaneous Epidural Stimulation | Neurostimulation User Experience | Stimulation | 2.917 Score on a scale | Standard Deviation 0.144 |
| Percutaneous Epidural Stimulation | Neurostimulation User Experience | Novelty | 2.583 Score on a scale | Standard Deviation 0.382 |
| Transcutaneous Epidural Stimulation | Neurostimulation User Experience | Stimulation | 2 Score on a scale | Standard Deviation 0.354 |
| Transcutaneous Epidural Stimulation | Neurostimulation User Experience | Attractiveness | 2.5 Score on a scale | Standard Deviation 0 |
| Transcutaneous Epidural Stimulation | Neurostimulation User Experience | Dependability | 1.75 Score on a scale | Standard Deviation 0.354 |
| Transcutaneous Epidural Stimulation | Neurostimulation User Experience | Perspicuity | 1.917 Score on a scale | Standard Deviation 0.382 |
| Transcutaneous Epidural Stimulation | Neurostimulation User Experience | Novelty | 1.75 Score on a scale | Standard Deviation 1.414 |
| Transcutaneous Epidural Stimulation | Neurostimulation User Experience | Efficiency | 2 Score on a scale | Standard Deviation 0.354 |
Neurostimulator Lead Location and Migration [Epidural Group Only]
Evaluation of current array location via CT.
Time frame: Pre-intervention and 4 weeks post-intervention
Population: Analysis applies only to percutaneous group participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Percutaneous Epidural Stimulation | Neurostimulator Lead Location and Migration [Epidural Group Only] | -5.35862 millimeters |
Overground Ambulation [as Appropriate to the Subject]
Measurement of changes in overground mobility as measured by the Modified 6 Minute Walk Test. Trainers will assess the distance in meters which the subject can cover in 6 minutes, with a greater distance characterizing better overground mobility.
Time frame: Baseline, 4 Weeks, 8 Weeks, and 20 Weeks
Population: No Transcutaneous Epidural Stimulation arm participants were ambulatory.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Percutaneous Epidural Stimulation | Overground Ambulation [as Appropriate to the Subject] | Pre-intervention to post-intervention | 9.2 meters |
| Percutaneous Epidural Stimulation | Overground Ambulation [as Appropriate to the Subject] | Pre-intervention to 8 weeks post intervention | 16.5 meters |
| Percutaneous Epidural Stimulation | Overground Ambulation [as Appropriate to the Subject] | Pre-intervention to 20 weeks post intervention | 16.5 meters |
Patient-reported Bladder Function
Measurement of change in bladder function using the Neurogenic Bladder Symptom Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bladder symptoms. The total score can range from 0 (no symptoms at all) to 74 (maximum symptoms).
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Percutaneous Epidural Stimulation | Patient-reported Bladder Function | -11.3 Score on a scale |
| Transcutaneous Epidural Stimulation | Patient-reported Bladder Function | -4.5 Score on a scale |
Patient-reported Bowel Function
Measurement of change in bowel function using the Neurogenic Bowel Dysfunction Score. Answers to qualitative questions are rated from 0 to 5, with a higher number indicating more problematic symptoms, and totaled for a score which categorizes severity of neurogenic bowel symptoms. The total score ranges between 0 and 44 points. A higher total score indicates more severe bowel symptoms.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Percutaneous Epidural Stimulation | Patient-reported Bowel Function | -4 Score on a scale |
| Transcutaneous Epidural Stimulation | Patient-reported Bowel Function | -3.5 Score on a scale |
Somatosensory Evoked Potentials
Measurements of change in voltage in the conduction of electricity through the peripheral nerves, cervical and lumbosacral spinal cord, deep brain structures, and sensory cortex, using surface electrodes.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
Population: Change in amplitude of lumbar SSEP during tibial stimulation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Percutaneous Epidural Stimulation | Somatosensory Evoked Potentials | Left sided measurements | 0.67 microvolts | Standard Deviation 0.6 |
| Percutaneous Epidural Stimulation | Somatosensory Evoked Potentials | Right sided measurements | 0.33 microvolts | Standard Deviation 0.12 |
| Transcutaneous Epidural Stimulation | Somatosensory Evoked Potentials | Left sided measurements | 0.8 microvolts | Standard Deviation 0.99 |
| Transcutaneous Epidural Stimulation | Somatosensory Evoked Potentials | Right sided measurements | 0.35 microvolts | Standard Deviation 0.07 |
Spasticity
Change in measurements of spasticity using the Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET). Answers to qualitative questions are rated from -3 to +3, with a higher positive number indicating more helpful symptoms, and a lower negative number indicating more problematic symptoms. Questions may also be answered as not applicable (N/A), which do not generate a score. Scores are totaled for a score which categorizes the overall positive or negative impact of a subject's spasticity symptoms. Total score can range from -105 (negative impact) to +105 (positive impact), and the score is averaged by total positive or negative score divided by the number of applicable answers.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Percutaneous Epidural Stimulation | Spasticity | 0.057 Score on a scale |
| Transcutaneous Epidural Stimulation | Spasticity | 0.088 Score on a scale |
Transcranial Magnetic Stimulation Motor Evoked Potentials
Measurement of the threshold percentage change in voltage between pre-intervention and post-intervention in the first trapezius or deltoid muscle activated.
Time frame: Assessed at Baseline, 4 Weeks, 8 Weeks, and 20 Weeks; change from Baseline at week 20 reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Percutaneous Epidural Stimulation | Transcranial Magnetic Stimulation Motor Evoked Potentials | 3.33 percent change | Standard Deviation 5.77 |
| Transcutaneous Epidural Stimulation | Transcranial Magnetic Stimulation Motor Evoked Potentials | 5 percent change | Standard Deviation 7.07 |
Trunk Stability
Changes in trunk stability based on stable forward reach measured in centimeters, with a greater distance of forward reach characterizing greater trunk stability. Specifically, change in forward reach at the end of the study when comparing stimulation assisted reach and non-stimulation assisted reach.
Time frame: Beginning of intervention to end of intervention, an average of 17 days, 8 weeks post beginning of intervention, 20 weeks post beginning of intervention; change from beginning of intervention at week 20 reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Percutaneous Epidural Stimulation | Trunk Stability | Non-stimulation assisted reach | 14.933333 centimeters | Standard Deviation 9.3972809 |
| Percutaneous Epidural Stimulation | Trunk Stability | Stimulation assisted reach | 34.933333 centimeters | Standard Deviation 14.115319 |
| Transcutaneous Epidural Stimulation | Trunk Stability | Non-stimulation assisted reach | 3 centimeters | Standard Deviation 3 |
| Transcutaneous Epidural Stimulation | Trunk Stability | Stimulation assisted reach | 21.5 centimeters | Standard Deviation 11 |